Monoclonal antibody therapy for resected Dukes' C colerectal cancer: Seven-year outcome of a multicenter randomized trial

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1788-1794

  Riethmuller G ^a   Holz, E ^a   Schlimok, G ^a   Schmiegel, W ^a   Raab, R ^a   Hoffken K ^a   Gruber, R ^a   Funke, I ^a   Pichlmaier, H ^a   Hirche, H ^a   Buggisch, P ^a   Witte, J ^a   Pichlmayr, R ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EDRECOLOMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0343965762     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1788     Document Type: Article

References (21)

1. McLaughlin P, Cabanillas F, Grillo-López A. et al: IDEC-C2B8 anti-CD20 antibody: Final report on a phase III pivotai trial in patients with relapsed low-grade or follicular lymphoma. Blood 88:90a, 1996 (suppl 1, abstr)
2. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
3. Riethmuller G, Schneider-Gädicke E, Schlimok G, et al: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177-1183, 1994
4. Herlyn D, Steplewski Z, Herlyn M, et al: Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76:1438-1442, 1979
5. Göttlinger HG, Funke I, Johnson JF, et al: The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38:47-53, 1986
6. Overgaard M, Hansen P, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949-955, 1997
7. Ragaz J, Jackson S, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
8. Zelen M: The randomisation and stratification of patients to clinical trials. J Chron Dis 27:365-375, 1974
9. Zelen M: A new design for randomized clinical trials. N Engl J Med 300:1242-1245, 1979
10. Herlyn D, Steplewski Z, Herlyn M, et al: Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 40:717-721, 1980
11. Litvinov S, Velders M, Bakker H, et al: Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125:437-446, 1994
12. Moertel C, Fleming T, Macdonald J: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
13. Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991
14. Wolmark N, Fisher B, Rockette H: Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 80:30-36, 1988
15. Panettiere F, Goodman P, Costanzi J, et al: Adjuvant therapy in large bowel adenocarcinoma: Long-term results of a Southwest Oncology Group study. J Clin Oncol 6:947-954, 1988
16. Pantel K, Schlimok G, Braun S, et al: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Nat Cancer Inst 85:1419-1424, 1993
17. Sears HF, Herlyn D, Koprowski H, et al: Immunotherapy of gastrointestinal malignancies with a murine IgG2A antibody, in Riethmüller G, Koprowski H, von Kleist S, et al: (eds): Genes and Antigens in Cancer Cells. Basel, Switzerland, Karger, 1984, pp 180-192
18. Gruber R, van Haarlem L, Warnaar S, et al: Anti-mouse immunoglobulin, anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibody response in patients with minimal residual colorectal cancer during monoclonal antibody therapy (17-1A): No correlation to clinical outcome, (submitted)
19. Fagerberg J, Steinitz M, Wigzell H, et al: Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 92:4773-4777, 1995
20. Pantel K, Braun S, Passlick B, et al: Minimal residual epithelial cancer: Diagnostic approaches and prognostic relevance. Prog Histochem Cytochem 30:1-43, 1996
21. Welt S, Scott A, Divgi C, et al: Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 14:1787-1797, 1996